People · Operator
Named in public records as an officer, director or promoter · active 2013–2021 · Biotechnology, Other Health Care, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ensoma, Inc. | — | Biotechnology | Series D+ | $169.6M | $2.3B | 2021 |
| Rallybio Holdings, LLC | — | Other Health Care | Series D+ | $157.8M | $69.6M | 2020 |
| Entrada Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $150.9M | $3.3B | 2016 |
| Akouos, Inc. | — | Biotechnology | Series D+ | $137.7M | $4.3B | 2017 |
| Arvinas, Inc. | — | Biotechnology | Series C | $129.1M | $1.3B | 2015 |
| Homology Medicines, Inc. | — | Pharmaceuticals | Series C | $127.1M | $2.9B | 2015 |
| Vor Biopharma Inc. | — | Pharma | Series D+ | $110.1M | $3.9B | 2020 |
| Audentes Therapeutics, Inc. | — | Biotechnology | Series C | $107.5M | $2.7B | 2014 |
| scPharmaceuticals Inc. | — | Pharmaceuticals | Series C | $71.8M | $1.6B | 2014 |
| Arvinas, Inc. | — | Pharmaceuticals | Seed | $3.5M | $133.6M | 2013 |
Kush Parmar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kush Parmar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tim Shannon | 3 | 9 |
| KUSH M. PARMAR | 3 | 3 |
| Jonathan Silverstein | 2 | 10 |
| Jonathan Soderstrom | 2 | 3 |
| Albert Seymour | 2 | 2 |
| Arthur Tzianabos | 2 | 2 |
| Steven Gillis | 1 | 23 |
| ANDREW LEVIN | 1 | 17 |
| Todd Foley | 1 | 12 |
| Joshua Resnick | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| Ed Mathers | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Cameron Wheeler | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Chris Smith | 1 | 7 |
| Sean Cassidy | 1 | 7 |
| Thomas Woiwode | 1 | 7 |
| Heather Preston | 1 | 6 |
| Vicki Sato | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.